Risk of malignancy in adrenal tumors in patients with a history of cancer
PurposeAdrenal gland is a common site of metastasis and on the other hand, metastases are the most frequent malignant adrenal tumors. The aim of this study was to estimate the risk of malignancy in suspicious adrenal mass in patients with a history of cancer.MethodsThis is a single-center retrospect...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1018475/full |
| _version_ | 1797859685116674048 |
|---|---|
| author | Radosław Samsel Karolina Nowak Lucyna Papierska Edyta Karpeta Edyta Karpeta Katarzyna Roszkowska-Purska Wacław Smiertka Tomasz Ostrowski Eryk Chrapowicki Alan Grabowski Dorota Leszczyńska Andrzej Cichocki |
| author_facet | Radosław Samsel Karolina Nowak Lucyna Papierska Edyta Karpeta Edyta Karpeta Katarzyna Roszkowska-Purska Wacław Smiertka Tomasz Ostrowski Eryk Chrapowicki Alan Grabowski Dorota Leszczyńska Andrzej Cichocki |
| author_sort | Radosław Samsel |
| collection | DOAJ |
| description | PurposeAdrenal gland is a common site of metastasis and on the other hand, metastases are the most frequent malignant adrenal tumors. The aim of this study was to estimate the risk of malignancy in suspicious adrenal mass in patients with a history of cancer.MethodsThis is a single-center retrospective analysis of patients with adrenal tumors treated previously for different types of cancers. Between 2004 and 2021 a hundred and six such patients were identified. Mean age of patients was 62.6 years (30-78), and mean time from oncologic treatment was 55.8 months (0-274). The most common primary cancer was kidney (RCC): 29 (27.4%), colon/rectum (CRC): 20 (18.9%) and lung (NSCLC): 20 (18.9%).ResultsOf 106 patients, 12 had hormonally active (HA) (11,3%) and 94 (88,7%) non active (HNA) tumors In group of patients with HA tumours 4 had hypercortisolaemia and 8 had elevation of urinary metanephrines. In the first group of HA patients pathology confirmed preoperative diagnosis of adrenocortical cancer and no metastasis was found. In all patients from the second group pheochromocytomas were confirmed. Primary (PM) and secondary (SM) malignancies were found in 50 patients (47.2%). In hormone inactive group only SM - 46/94 (48.9%) were diagnosed. The odds that adrenal lesion was a metastasis were higher if primary cancer was RCC (OR 4.29) and NSCLC (OR 12.3). Metastases were also more likely with high native tumor density, and bigger size in CT. The cut-off values for tumor size and native density calculated from receiver operating characteristic (ROC) curves were 37mm and 24, respectively.ConclusionRisk of malignancy of adrenal mass in a patient with a history of cancer is high (47,2%), regardless of hormonal status. 47,2% risk of malignancy. In preoperative assessment type of primary cancer, adrenal tumour size and native density on CT should be taken into consideration as predictive factors of malignancy. Native density exceeding 24 HU was the strongest risk factor of adrenal malignancy (RR 3.23), followed by history of lung or renal cancer (RR 2.82) and maximum tumor diameter over 37 mm (RR 2.14). |
| first_indexed | 2024-04-09T21:33:37Z |
| format | Article |
| id | doaj.art-51282ac078c648ada2e5bf6a1a815e6c |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-09T21:33:37Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-51282ac078c648ada2e5bf6a1a815e6c2023-03-27T05:30:03ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-03-011310.3389/fonc.2023.10184751018475Risk of malignancy in adrenal tumors in patients with a history of cancerRadosław Samsel0Karolina Nowak1Lucyna Papierska2Edyta Karpeta3Edyta Karpeta4Katarzyna Roszkowska-Purska5Wacław Smiertka6Tomasz Ostrowski7Eryk Chrapowicki8Alan Grabowski9Dorota Leszczyńska10Andrzej Cichocki11Department of Surgery, Clinic of Surgical Oncology and Neuroendocrine Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PolandDepartment of Endocrinology, Medical Centre of Postgraduate Education, Bielański Hospital, Warsaw, PolandDepartment of Endocrinology, Medical Centre of Postgraduate Education, Bielański Hospital, Warsaw, PolandDepartment of Surgical and Transplantation Nursing and Extracorporeal Therapies, Medical University of Warsaw, Warsaw, PolandDepartment of General and Transplant Surgery , Medical University of Warsaw, Warsaw, PolandDepartment of Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PolandDepartment of Surgery, Clinic of Surgical Oncology and Neuroendocrine Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PolandDepartment of Surgery, Clinic of Surgical Oncology and Neuroendocrine Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PolandDepartment of Surgery, Clinic of Surgical Oncology and Neuroendocrine Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PolandDepartment of Surgery, Clinic of Surgical Oncology and Neuroendocrine Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PolandDepartment of Endocrinology, Medical Centre of Postgraduate Education, Bielański Hospital, Warsaw, PolandDepartment of Surgery, Clinic of Surgical Oncology and Neuroendocrine Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PolandPurposeAdrenal gland is a common site of metastasis and on the other hand, metastases are the most frequent malignant adrenal tumors. The aim of this study was to estimate the risk of malignancy in suspicious adrenal mass in patients with a history of cancer.MethodsThis is a single-center retrospective analysis of patients with adrenal tumors treated previously for different types of cancers. Between 2004 and 2021 a hundred and six such patients were identified. Mean age of patients was 62.6 years (30-78), and mean time from oncologic treatment was 55.8 months (0-274). The most common primary cancer was kidney (RCC): 29 (27.4%), colon/rectum (CRC): 20 (18.9%) and lung (NSCLC): 20 (18.9%).ResultsOf 106 patients, 12 had hormonally active (HA) (11,3%) and 94 (88,7%) non active (HNA) tumors In group of patients with HA tumours 4 had hypercortisolaemia and 8 had elevation of urinary metanephrines. In the first group of HA patients pathology confirmed preoperative diagnosis of adrenocortical cancer and no metastasis was found. In all patients from the second group pheochromocytomas were confirmed. Primary (PM) and secondary (SM) malignancies were found in 50 patients (47.2%). In hormone inactive group only SM - 46/94 (48.9%) were diagnosed. The odds that adrenal lesion was a metastasis were higher if primary cancer was RCC (OR 4.29) and NSCLC (OR 12.3). Metastases were also more likely with high native tumor density, and bigger size in CT. The cut-off values for tumor size and native density calculated from receiver operating characteristic (ROC) curves were 37mm and 24, respectively.ConclusionRisk of malignancy of adrenal mass in a patient with a history of cancer is high (47,2%), regardless of hormonal status. 47,2% risk of malignancy. In preoperative assessment type of primary cancer, adrenal tumour size and native density on CT should be taken into consideration as predictive factors of malignancy. Native density exceeding 24 HU was the strongest risk factor of adrenal malignancy (RR 3.23), followed by history of lung or renal cancer (RR 2.82) and maximum tumor diameter over 37 mm (RR 2.14).https://www.frontiersin.org/articles/10.3389/fonc.2023.1018475/fulladrenal tumorsadrenal malignancyadrenal metastasesadrenalectomyrisk of adrenal malignancy |
| spellingShingle | Radosław Samsel Karolina Nowak Lucyna Papierska Edyta Karpeta Edyta Karpeta Katarzyna Roszkowska-Purska Wacław Smiertka Tomasz Ostrowski Eryk Chrapowicki Alan Grabowski Dorota Leszczyńska Andrzej Cichocki Risk of malignancy in adrenal tumors in patients with a history of cancer Frontiers in Oncology adrenal tumors adrenal malignancy adrenal metastases adrenalectomy risk of adrenal malignancy |
| title | Risk of malignancy in adrenal tumors in patients with a history of cancer |
| title_full | Risk of malignancy in adrenal tumors in patients with a history of cancer |
| title_fullStr | Risk of malignancy in adrenal tumors in patients with a history of cancer |
| title_full_unstemmed | Risk of malignancy in adrenal tumors in patients with a history of cancer |
| title_short | Risk of malignancy in adrenal tumors in patients with a history of cancer |
| title_sort | risk of malignancy in adrenal tumors in patients with a history of cancer |
| topic | adrenal tumors adrenal malignancy adrenal metastases adrenalectomy risk of adrenal malignancy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1018475/full |
| work_keys_str_mv | AT radosławsamsel riskofmalignancyinadrenaltumorsinpatientswithahistoryofcancer AT karolinanowak riskofmalignancyinadrenaltumorsinpatientswithahistoryofcancer AT lucynapapierska riskofmalignancyinadrenaltumorsinpatientswithahistoryofcancer AT edytakarpeta riskofmalignancyinadrenaltumorsinpatientswithahistoryofcancer AT edytakarpeta riskofmalignancyinadrenaltumorsinpatientswithahistoryofcancer AT katarzynaroszkowskapurska riskofmalignancyinadrenaltumorsinpatientswithahistoryofcancer AT wacławsmiertka riskofmalignancyinadrenaltumorsinpatientswithahistoryofcancer AT tomaszostrowski riskofmalignancyinadrenaltumorsinpatientswithahistoryofcancer AT erykchrapowicki riskofmalignancyinadrenaltumorsinpatientswithahistoryofcancer AT alangrabowski riskofmalignancyinadrenaltumorsinpatientswithahistoryofcancer AT dorotaleszczynska riskofmalignancyinadrenaltumorsinpatientswithahistoryofcancer AT andrzejcichocki riskofmalignancyinadrenaltumorsinpatientswithahistoryofcancer |